VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ICLR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ICLRICON Public Limited Company
$168.72$12.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ICLR logoICON Public Limited Company(ICLR)Earnings, Financials & Key Ratios

ICLR•NASDAQ
$168.72
58.2× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryContract Research and Preclinical Services
AboutICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.Show more
  • Revenue$8.25B-0.4%
  • EBITDA$1.4B-12.0%
  • Net Income$229M-71.0%
  • EPS (Diluted)2.90-69.6%
  • Gross Margin26.37%-10.4%
  • EBITDA Margin16.91%-11.7%
  • Operating Margin12.27%-7.4%
  • Net Margin2.78%-70.9%
  • ROE2.45%-71.0%

ICLR Price & Volume

ICON Public Limited Company (ICLR) stock price & volume — 10-year historical chart

Loading chart...

Stagnant Revenue Growth Pressures ICON Operating Margins

Investment Thesis • Updated 2026Q1

VerdictNegative: The company's inability to drive top-line growth beyond 1.6% in 2026Q1
Growth:Decelerating
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Margin compression from labor

Key Thesis Takeaways

  • ICON faces a challenging transition as revenue growth has decelerated to 1.6% in 2026Q1, signaling potential saturation in its core clinical research service delivery.
  • While the company maintains a disciplined debt-to-equity ratio of 0.38, the significant concentration of $8.7 billion in goodwill remains a primary risk factor for future impairment.
  • Investors should monitor whether the firm can improve its current 8.5% operating margin, as aggressive capital allocation through share repurchases may be premature given the current volatility in earnings quality.

Verdict Logic

combined with a significant contraction in operating margins to 8.5%, suggests that current valuation multiples may not fully account for the underlying operational headwinds.

ICLR Growth Metrics

ICON Public Limited Company (ICLR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years18.01%
5 Years24.15%
3 Years2.15%
TTM0.17%

Profit CAGR

10 Years-0.43%
5 Years-6.9%
3 Years-23.15%
TTM-42.06%

EPS CAGR

10 Years-3.09%
5 Years-14.21%
3 Years-22.08%
TTM-38.78%

Return on Capital

10 Years14.58%
5 Years6.34%
3 Years7.3%
Last Year7.46%

ICLR Recent Earnings

ICON Public Limited Company (ICLR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q3 2026Latest
Jun 23, 2026
Metric
Actual
Est
EPS
$2.50+2.9%
$2.43
Rev
$2.1B+6.6%
$2.0B
Q2 2026
May 28, 2026
Metric
Actual
Est
EPS
$2.52-14.6%
$2.95
Rev
$2.1B+6.6%
$2.0B
Q2 2026
May 27, 2026
Metric
Actual
Est
EPS
$2.52+3.7%
$2.43
Rev
$2.1B+6.6%
$2.0B
Q2 2026
Apr 29, 2026
Metric
Actual
Est
EPS
$3.28+2.8%
$3.19
Rev
$2.0B+0.5%
$2.0B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026LatestJun 23, 2026
$2.50vs $2.43+2.9%
$2.1Bvs $2.0B+6.6%
Q2 2026May 28, 2026
$2.52vs $2.95-14.6%
$2.1Bvs $2.0B+6.6%
Q2 2026May 27, 2026
$2.52vs $2.43+3.7%
$2.1Bvs $2.0B+6.6%
Q2 2026Apr 29, 2026
$3.28vs $3.19+2.8%
$2.0Bvs $2.0B+0.5%
Based on last 12 quarters of dataView full earnings history →

Latest ICLR News

Recent stock market news and headlines for ICON Public Limited Company (ICLR)

Seeking Alpha·Jun 25, 2026
ICON Q1 2026: Margins Face Questions, But The Long-Term Thesis Holds

ICON plc delivered a modest 1Q26 beat, with EPS of $2.50 and revenue of $2.03B, but growth was subdued and margins compressed. ICLR reaffirmed FY26 guidance—revenue of $7.85–$8.15B and EPS of $10–$11—signaling management confidence in a back-half recovery. Profitability faced pressure as adjusted EBITDA fell over 20% and margins dropped to 15.6%, driven by business mix and integration costs.

The Motley Fool·Jun 24, 2026
Why Icon Stock Crushed it on Wednesday

It posted mixed results, but investors looked past this to other encouraging developments. In particular, this included gross bookings for the period.

Seeking Alpha·Jun 24, 2026
ICON Public Limited Company (ICLR) Q1 2026 Earnings Call Transcript

ICON Public Limited Company (ICLR) Q1 2026 Earnings Call Transcript

Business Wire·Jun 23, 2026
ICON Reports First Quarter 2026 Results

DUBLIN--(BUSINESS WIRE)--ICON Reports First Quarter 2026 Results.

Business Wire·Jun 22, 2026
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced that it has selected Microsoft as a preferred technology partner – further advancing ICON's previously announced plan to invest in digital innovation and AI over the next three years. This partnership incorporates an enterprise-wide deployment of Microsoft 365 Copilot along with an enterprise-grade cloud, data and AI infrastructure to further scale Orbis, ICON's secure, governed agentic AI platform. Through Orbis, ICON is building.

Peers Comparison

Key metrics vs top competitors for ICON Public Limited Company (ICLR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ICLR logoICLRICON Public Limited CompanyCurrent
$168.72$12.92B58.18-0.37%2.78%2.45%—
CRL logoCRLCharles River Laboratories International, Inc.
$228.68$11.01B-78.58-0.85%-4.59%-5.66%—
IQV logoIQVIQVIA Holdings Inc.
$208.23$35.34B26.565.87%8.33%22.11%—
MEDP logoMEDPMedpace Holdings, Inc.
$546.29$15.6B35.7519.97%17.19%120.89%—
PRA logoPRAProAssurance Corporation
$25.00$1.29B25.25-2.67%6.04%4.95%—
LH logoLHLabcorp Holdings Inc.
$283.86$23.36B27.147.25%6.66%10.89%—

Compare ICLR vs Peers

ICON Public Limited Company (ICLR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CRL

Most directly comparable listed peer for ICLR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare ICLR against a more recognizable public peer.

Peer Set

Compare Top 5

vs CRL, IQV, MEDP, PRA

Get notified when ICLR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ICLR Frequently Asked Questions

ICON Public Limited Company (ICLR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is ICON Public Limited Company's revenue?

ICON Public Limited Company (ICLR) reported $8.21B in revenue for fiscal year 2025. This represents a 14607% increase from $55.8M in 1998.

How fast is ICON Public Limited Company growing?

ICON Public Limited Company (ICLR) saw revenue decline by 0.4% over the past year.

Is ICLR profitable?

Yes, ICON Public Limited Company (ICLR) is profitable, generating $439.3M in net income for fiscal year 2025 (2.8% net margin).

Dividend & Returns
What is ICLR's return on equity?

ICON Public Limited Company (ICLR) has a return on equity (ROE) of 2.5%. This is below average, suggesting room for improvement.

What is ICON Public Limited Company's free cash flow?

ICON Public Limited Company (ICLR) generated $1.24B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ICLR back in 1998?

Total return calculator · dividends reinvested · 28+ years of data

See returns →